Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In this study, we investigated the immunomodulatory effects of melatonin on B-cell maturation and its potential to mitigate immunodeficiency following transient focal cerebral ischemia in mice. Transient middle cerebral artery occlusion (MCAO) was induced in adult C57BL/6 mice, followed by melatonin administration. We evaluated the effects of melatonin on neutrophil infiltration, macrophage and microglial activation in the ischemic brain, and B-cell maturation in both the central nervous system and peripheral blood. Melatonin treatment significantly reduced pro-inflammatory cell infiltration in the ischemic hemisphere and promoted B-cell maturation, reflecting robust immunomodulatory activity. These immune changes coincided with improved neurological outcomes and reduced cerebral edema. Collectively, our findings suggest that melatonin may serve as a promising therapeutic candidate in ischemic stroke, addressing both immunodeficiency and neuronal injury.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11481-025-10222-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lymphotoxin beta receptor mice display altered B- and T-cell subpopulations in the bone marrow and peritoneal cavity after infection.
Infect Immun
September 2025
Institute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University, Düsseldorf, Germany.
Lymphotoxin β receptor (LTβR/TNFRSF3) signaling plays a crucial role in immune defense. Notably, LTβR-deficient (LTβR) mice exhibit severe defects in innate and adaptive immunity against various pathogens and succumb to infection. Here, we investigated the bone marrow (BM) and peritoneal cavity (PerC) compartments of LTβR mice during infection, demonstrating perturbed B-cell and T-cell subpopulations in the absence of LTβR signaling.
View Article and Find Full Text PDFComparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies.
Ann Hematol
September 2025
Excellence Center for Comprehensive Cancer (ECCCC), King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Despite therapeutic advances, multiple myeloma (MM) remains incurable, especially in relapsed/refractory (R/R) cases. B-cell maturation antigen (BCMA) is a key target for novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific T-cell engagers (BiTEs), which vary in efficacy, toxicity, and accessibility. To compare the efficacy and safety of BCMA-directed CAR-T therapies and BiTEs in R/R MM through a systematic review and meta-analysis.
View Article and Find Full Text PDFPrognostic Value of C-Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma.
Hematol Oncol
September 2025
Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Previous studies have shown that the pre-transplant C-reactive protein (CRP)/platelet ratio (CP ratio) is a predictor of survival. The aim of this multicenter retrospective study was to evaluate the clinical significance of CP ratio in patients with malignant lymphoma (ML) who underwent allogeneic hematopoietic stem cell transplantation (alloHCT). The cohort included patients with ML who underwent first alloHCT from 2007 to 2021.
View Article and Find Full Text PDFIGHA1 and IGHG1 Expression Panel Predicts Anti-PD-L1 Response in Muscle-Invasive Bladder Cancer.
Mol Carcinog
September 2025
Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
B cells located in tertiary lymphoid structures (TLSs) may undergo clonal expansion, somatic hypermutation, isotype switching, and tumor-specific antibody production, suggesting that antibody-producing plasma cells may be involved in antitumor immunity. This study used a combination of single-cell sequencing (five samples from our center, and four samples from PRJNA662018) and spatial transcriptome (one sample from our center, and four samples from GSE169379) research methods to investigate the relationship between TLSs and the immunoglobulin repertoire in muscle invasive bladder cancer (MIBC). 405 patients with MIBC from TCGA and 348 patients with metastatic urothelial carcinoma on PD-L1 inhibitor treatment from the IMvigor210 trial were included in this study.
View Article and Find Full Text PDFDistinct effects of adjuvants on B cell responses to protein or polysaccharide antigens contained in glycoconjugate vaccines.
Front Immunol
September 2025
Bacterial Scientific Area, GSK Vaccine, Siena, Italy.
Background: Protein-polysaccharide conjugate vaccines rely on the induction of T-cell-dependent responses that support germinal center (GC) reactions to potentiate the expansion of antigen-specific memory B-cell (MBC) populations and high-avidity antibody responses. The effects of adjuvants on B-cell and antibody responses are well described for protein antigens but remain largely unexplored for conjugated polysaccharidic antigens.
Methods: We assessed the effects of five adjuvants present in licensed vaccines (AS01, AS03, AS04, and aluminum hydroxide [Alum]) or under clinical evaluation (AS37) on the magnitude and quality of antigen-specific antibody responses and local/systemic B-cell responses.